Los Angeles Capital Management
KNSA icon

Los Angeles Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Los Angeles Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.25M Buy
50,786
+34,557
+213% +$1.79M 0.01% 489
2026
Q1 		$781K Sell
16,229
-7,430
-31% -$329K ﹤0.01% 747
2025
Q4 		$882K Buy
23,659
+5,376
+29% +$216K ﹤0.01% 678
2025
Q3 		$710K Buy
18,283
+10,246
+127% +$333K ﹤0.01% 812
2025
Q2 		$222K Sell
8,037
-36,570
-82% -$931K ﹤0.01% 1155
2025
Q1 		$991K Sell
44,607
-10,921
-20% -$225K ﹤0.01% 567
2024
Q4 		$1.1M Sell
55,528
-44,473
-44% -$1.02M ﹤0.01% 588
2024
Q3 		$2.5M Buy
100,001
+20,801
+26% +$507K 0.01% 416
2024
Q2 		$1.48M Sell
79,200
-60,650
-43% -$1.14M 0.01% 524
2024
Q1 		$2.76M Sell
139,850
-7,332
-5% -$143K 0.01% 427
2023
Q4 		$2.58M Buy
147,182
+1,540
+1% +$25.3K 0.01% 427
2023
Q3 		$2.53M Sell
145,642
-14,752
-9% -$249K 0.01% 400
2023
Q2 		$2.26M Buy
160,394
+46,747
+41% +$626K 0.01% 465
2023
Q1 		$1.22M Sell
113,647
-4,059
-3% -$53.5K 0.01% 609
2022
Q4 		$1.76M Sell
117,706
-5,284
-4% -$76.9K 0.01% 548
2022
Q3 		$1.58M Buy
122,990
+57,408
+88% +$654K 0.01% 566
2022
Q2 		$635K Buy
65,582
+260
+0.4% +$2.43K ﹤0.01% 878
2022
Q1 		$649K Buy
65,322
+5,352
+9% +$56.7K ﹤0.01% 926
2021
Q4 		$706K Buy
59,970
+27,886
+87% +$343K ﹤0.01% 854
2021
Q3 		$365K Sell
32,084
-13,692
-30% -$178K ﹤0.01% 1213
2021
Q2 		$638K Buy
45,776
+23,463
+105% +$356K ﹤0.01% 1061
2021
Q1 		$413K Sell
22,313
-5,810
-21% -$119K ﹤0.01% 1302
2020
Q4 		$497K Buy
28,123
+1,591
+6% +$27.9K ﹤0.01% 1210
2020
Q3 		$406K Buy
26,532
+4,179
+19% +$78.5K ﹤0.01% 1167
2020
Q2 		$570K Buy
22,353
+4,413
+25% +$92.2K ﹤0.01% 1061
2020
Q1 		$278K Buy
17,940
+4,900
+38% +$76.7K ﹤0.01% 1078
2019
Q4 		$144K Buy
+13,040
New +$113K ﹤0.01% 1222

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Los Angeles Capital Management's KNSA Position: Q2 2026 in Review

Los Angeles Capital Management increased its Kiniksa Pharmaceuticals (KNSA) stake by 213% in Q2 2026, buying an estimated $1.79M and bringing the position to 50,786 shares worth $3.25M. The position accounts for 0.01% of the portfolio, ranked #489.

Los Angeles Capital Management first reported a position in KNSA in Q4 2019 and has held it in 27 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Los Angeles Capital Management held 50,786 shares of Kiniksa Pharmaceuticals worth $3.25M as of Q2 2026.
  • Los Angeles Capital Management bought 34,557 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $1.79M.
  • Kiniksa Pharmaceuticals made up 0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #489 holding.
  • Los Angeles Capital Management first reported a position in Kiniksa Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.